Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Dermatology Therapeutics Market to 2017 - Introduction | 9 | 1 |
| Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Dermatology Therapeutics Market to 2017 - Market Overview | 10 | 4 |
| Introduction | 10 | 1 |
| Annual Cost of Treatment | 11 | 1 |
| Treatment Usage Pattern | 12 | 1 |
| Diseased Population | 13 | 1 |
| Treatment Seeking Population | 13 | 1 |
| Diagnosed Population | 13 | 1 |
| Prescription Population | 13 | 1 |
| Dermatology Therapeutics Market to 2017 - Geographical Landscape | 14 | 16 |
| Geographical Break-up | 14 | 2 |
| The US | 16 | 1 |
| Revenue | 16 | 1 |
| Annual Cost of Treatment | 17 | 1 |
| Treatment Usage Pattern | 18 | 1 |
| Diseased Population | 19 | 1 |
| Treatment Seeking Population | 19 | 1 |
| Diagnosed Population | 19 | 1 |
| Prescription Population | 19 | 1 |
| Top Five Countries in Europe | 20 | 1 |
| Revenue | 20 | 3 |
| Annual Cost of Treatment | 23 | 1 |
| Treatment Usage Pattern | 24 | 1 |
| Diseased Population | 25 | 1 |
| Treatment Seeking Population | 25 | 1 |
| Diagnosed Population | 25 | 1 |
| Prescription Population | 25 | 1 |
| Japan | 26 | 1 |
| Revenue | 26 | 1 |
| Annual Cost of Treatment | 27 | 1 |
| Treatment Usage Pattern | 28 | 1 |
| Diseased Population | 29 | 1 |
| Treatment Seeking Population | 29 | 1 |
| Diagnosed Population | 29 | 1 |
| Prescription Population | 29 | 1 |
| Dermatology Therapeutics Market to 2017 - Therapeutic Landscape | 30 | 61 |
| Global Alopecia Therapeutics Market | 30 | 1 |
| Introduction | 30 | 2 |
| Revenue | 32 | 1 |
| Revenue by Country | 33 | 1 |
| Branded versus Generics | 34 | 1 |
| Annual Cost of Treatment | 35 | 1 |
| Treatment Usage Pattern | 36 | 1 |
| Diseased Population | 37 | 1 |
| Treatment Seeking Population | 37 | 1 |
| Diagnosed Population | 37 | 1 |
| Prescription Population | 37 | 1 |
| Treatment Algorithm | 38 | 1 |
| Drivers and Restraints for the Alopecia Market | 38 | 1 |
| Drivers | 38 | 1 |
| Restraints | 39 | 1 |
| Global Herpes Therapeutics Market: Market Characterization | 40 | 1 |
| Introduction | 40 | 3 |
| Revenue | 43 | 1 |
| Revenue by Country | 44 | 2 |
| Branded versus Generics | 46 | 1 |
| Annual Cost of Treatment | 47 | 1 |
| Treatment Usage Pattern | 48 | 1 |
| Diseased Population | 49 | 1 |
| Treatment Seeking Population | 49 | 1 |
| Diagnosed Population | 49 | 1 |
| Prescription Population | 49 | 1 |
| Treatment Algorithm | 50 | 1 |
| Drivers and Restraints for the Herpes Therapeutics Market | 51 | 1 |
| Drivers | 51 | 1 |
| Restraints | 51 | 1 |
| Global Psoriasis Therapeutics Market | 52 | 1 |
| Introduction | 52 | 1 |
| Revenue | 53 | 1 |
| Revenue by Country | 54 | 1 |
| Branded versus Generics | 55 | 1 |
| Annual Cost of Treatment | 56 | 1 |
| Treatment Usage Pattern | 57 | 1 |
| Diseased Population | 58 | 1 |
| Treatment Seeking Population | 58 | 1 |
| Diagnosed Population | 58 | 1 |
| Prescription Population | 58 | 1 |
| Treatment Algorithm | 59 | 1 |
| Drivers and Restraints for Psoriasis Market | 59 | 1 |
| Drivers | 59 | 1 |
| Restraints | 60 | 1 |
| Global Acne Therapeutics Market | 61 | 1 |
| Introduction | 61 | 1 |
| Revenue | 62 | 1 |
| Revenue by Country | 63 | 1 |
| Branded versus Generics | 64 | 1 |
| Annual Cost of Treatment | 65 | 1 |
| Treatment Usage Pattern | 66 | 1 |
| Diseased Population | 67 | 1 |
| Treatment Seeking Population | 67 | 1 |
| Diagnosed Population | 67 | 1 |
| Prescription Population | 67 | 1 |
| Treatment Algorithm | 68 | 1 |
| Drivers and Restraints for the Acne Therapeutics Market | 68 | 1 |
| Drivers | 68 | 1 |
| Restraints | 69 | 1 |
| Global Rosacea Disease Therapeutics Market | 70 | 1 |
| Introduction | 70 | 1 |
| Revenue | 71 | 1 |
| Revenue by Country | 72 | 1 |
| Branded versus Generics | 73 | 1 |
| Annual Cost of Treatment | 74 | 2 |
| Treatment Usage Pattern | 76 | 1 |
| Diseased Population | 77 | 1 |
| Treatment Seeking Population | 77 | 1 |
| Diagnosed Population | 77 | 1 |
| Prescription Population | 77 | 1 |
| Treatment Algorithm | 78 | 1 |
| Drivers and Restraints for the Rosacea Therapeutics Market | 79 | 1 |
| Drivers | 79 | 1 |
| Restraints | 79 | 1 |
| Global Atopic Dermatitis Therapeutics Market | 80 | 1 |
| Introduction | 80 | 1 |
| Revenue | 80 | 2 |
| Revenue by Country | 82 | 2 |
| Branded versus Generics | 84 | 1 |
| Annual Cost of Treatment | 85 | 1 |
| Treatment Usage Pattern | 86 | 1 |
| Diseased Population | 87 | 1 |
| Treatment Seeking Population | 87 | 1 |
| Diagnosed Population | 87 | 1 |
| Prescription Population | 87 | 1 |
| Treatment Algorithm | 88 | 1 |
| Drivers and Restraints for the Atopic Dermatitis Therapeutics Market | 89 | 1 |
| Drivers | 89 | 1 |
| Restraints | 90 | 1 |
| Dermatological Therapeutics Market to 2017 - Pipeline Analysis | 91 | 17 |
| Introduction | 91 | 1 |
| Research and Development Pipeline - Alopecia | 92 | 1 |
| Research and Development Pipeline - Herpes | 93 | 2 |
| Research and Development Pipeline - Psoriasis | 95 | 4 |
| Research and Development Pipeline - Acne | 99 | 2 |
| Research and Development Pipeline - Rosacea | 101 | 1 |
| Research and Development Pipeline - Atopic Dermatitis | 102 | 3 |
| Profiles of Promising Molecules in the Dermatology Therapeutics Market | 105 | 1 |
| LAS 41002 | 105 | 1 |
| Introduction | 105 | 1 |
| Mechanism of Action | 105 | 1 |
| Clinical Trial Management | 106 | 1 |
| Duac Low Dose | 106 | 1 |
| Introduction | 106 | 1 |
| Mechanism of Action | 106 | 1 |
| Clinical Trial Management | 107 | 1 |
| Clindamycin + Tretinoin | 107 | 1 |
| Introduction | 107 | 1 |
| Mechanism of Action | 107 | 1 |
| Clinical Trial Management | 107 | 1 |
| Dermatology Therapeutics Market to 2017 - Competitive Landscape | 108 | 11 |
| Market Share Analysis - Dermatological Disorders | 108 | 1 |
| Competitive Profiling | 109 | 1 |
| Centocor Ortho Biotech Inc | 109 | 1 |
| Company Overview | 109 | 1 |
| Product Portfolio | 109 | 1 |
| SWOT Analysis | 110 | 1 |
| Amgen | 110 | 1 |
| Company Overview | 110 | 1 |
| Product Portfolio | 111 | 1 |
| SWOT Analysis | 111 | 1 |
| Abbott Laboratories | 112 | 1 |
| Company Overview | 112 | 1 |
| Product Portfolio | 112 | 1 |
| SWOT Analysis | 113 | 1 |
| Merck &Co., Inc. | 113 | 1 |
| Company Overview | 113 | 1 |
| Product Portfolio | 114 | 1 |
| SWOT Analysis | 114 | 1 |
| Novartis AG | 115 | 1 |
| Company Overview | 115 | 1 |
| Product Portfolio | 115 | 1 |
| SWOT Analysis | 116 | 1 |
| GlaxoSmithKline plc. | 116 | 1 |
| Company Overview | 116 | 1 |
| Product Portfolio | 116 | 2 |
| SWOT Analysis | 118 | 1 |
| Dermatology Therapeutics Market to 2017 - Strategic Consolidations | 119 | 8 |
| Mergers and Acquisitions | 119 | 1 |
| Deals by Indication | 119 | 1 |
| Deals by Geography | 120 | 1 |
| Deals by Value | 121 | 1 |
| Major M&A Deals | 122 | 1 |
| GlaxoSmithKline (GSK) and Stiefel Laboratories | 122 | 1 |
| Nycomed and Bradley Pharmaceuticals | 122 | 1 |
| Bayer and Skin Medica, Inc. | 122 | 1 |
| Connetics Acquires Rights to Soriatane from Roche | 122 | 1 |
| LEO Pharma Acquires US Rights of Psoriasis Portfolio from Warner Chilcott | 122 | 1 |
| Licensing Agreements | 123 | 1 |
| Deals by Indication | 123 | 1 |
| Deals by Geography | 124 | 1 |
| Deals by Value | 125 | 1 |
| Major Licensing Agreements | 126 | 1 |
| Xenova Group Enters into Licensing Agreement with Oxxon Therapeutics | 126 | 1 |
| Medivir Enters into Licensing Agreement with Presidio | 126 | 1 |
| GlaxoSmithKline Enters into Licensing Agreement with NanoBio | 126 | 1 |
| Dermatology Therapeutics Market to 2017 - Appendix | 127 | 8 |
| Market Definitions | 127 | 1 |
| Abbreviations | 127 | 1 |
| Research Methodology | 128 | 2 |
| Coverage | 128 | 1 |
| Secondary Research | 129 | 1 |
| Primary Research | 129 | 1 |
| Therapeutic Landscape | 130 | 3 |
| Epidemiology-Based Forecasting | 130 | 2 |
| Market Size by Geography | 132 | 1 |
| Geographical Landscape | 133 | 1 |
| Pipeline Analysis | 133 | 1 |
| Competitive Landscape | 133 | 1 |
| Expert Panel Validation | 133 | 1 |
| Contact Us | 133 | 1 |
| Disclaimer | 133 | 1 |
| Sources | 134 | 1 |